| Literature DB >> 28843049 |
Abstract
BACKGROUND This research aimed to explore the effects of interferon-γ (IFN-γ) polymorphisms and expression profile on susceptibility to ankylosing spondylitis (AS) in a Chinese population. MATERIAL AND METHODS Blood samples were collected from 89 AS patients and 106 healthy controls. IFN-γ polymorphisms were genotyped by polymerase chain reaction (PCR) and sequencing methods. The genotype distribution of polymorphism in the control group was detected by Hardy-Weinberg equilibrium (HWE). Odds ratios (OR) with 95% confidence intervals (95%CI) were calculated using the χ² test to evaluate the association between AS susceptibility and IFN-γ polymorphisms. Moreover, serum IFN-γ level was measured by ELISA. RESULTS rs1861493 and rs2430561 polymorphisms were conformed to be in HWE in genotypes distribution of the control group (P>0.05 for both). However, only TT genotype and T allele of rs2430561 presented significantly higher frequencies in AS patients than in healthy controls (P=0.04 and 0.03, respectively), indicating that they obviously increased the risk of AS in a Chinese population (OR=2.54, 95%CI=1.01-6.40; OR=1.60, 95%CI=1.04-2.46). In AS patients, serum IFN-γ level was higher than in controls, and its expression patterns showed significant association with genotypes of rs2430561. CONCLUSIONS IFN-γ rs2430561 polymorphism may contribute to the risk of AS through influencing IFN-γ expression.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28843049 PMCID: PMC5584821 DOI: 10.12659/msm.902822
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
The primer sequences of IFN-γ polymorphisms.
| Polymorphism | Position | Primer sequence | |
|---|---|---|---|
| rs1861493 | Intron3 | For. | 5′-AGCAACAGCAAGGCGAAAAA-3′ |
| Rev. | 5′-TGGTGGACCACTCGGATGA-3′ | ||
| rs2430561 | Intron1 | For. | 5′-TCAACAAAGCTGATACTCCA-3′ |
| Rev. | 5′TTCTTACAACACAAAATCAAATCA-3′ |
Genotype and allele distributions of IFN-γ polymorphisms between case and control groups.
| Genotype/allele | Cases/% | Control/% | P | OR (95%CI) | PHWE |
|---|---|---|---|---|---|
| rs1861493 | 0.35 | ||||
| GG | 16/17.98 | 13/12.27 | 0.12 | 1.96 (0.83–4.61) | |
| AG | 41/46.07 | 42/39.62 | 0.16 | 1.56 (0.84–2.88) | |
| AA | 32/35.95 | 51/48.11 | – | 1.00 (Ref.) | |
| G | 73/41.01 | 68/32.08 | 0.07 | 1.47 (0.97–2.23) | |
| A | 105/58.99 | 144/67.92 | – | 1.00 (Ref.) | |
| rs2430561 | 0.51 | ||||
| TT | 15/16.85 | 9/8.49 | 0.04 | 2.54 (1.01–6.40) | |
| AT | 36/40.45 | 39/36.79 | 0.27 | 1.41 (0.77–2.59) | |
| AA | 38/42.70 | 58/54.72 | – | 1.00 (Ref.) | |
| T | 66/37.08 | 57/26.89 | 0.03 | 1.60 (1.04–2.46) | |
| A | 112/62.92 | 155/73.11 | – | 1.00 (Ref.) |
Figure 1The expression patterns of serum IFN-γ in the case and control groups (A); The comparison of serum IFN-γ level between GG, AG, and AA genotypes of rs1861493 in patients with ankylosing spondylitis (B); The comparison of serum IFN-γ level based on genotypes of rs2430561 in patients with ankylosing spondylitis (C).